Relief from neuropathic pain by blocking of the platelet-activating factor-pain loop.
Shindou H, Shiraishi S, Tokuoka SM, Takahashi Y, Harayama T, Abe T, Bando K, Miyano K, Kita Y, Uezono Y, Shimizu T.
Shindou H, et al.
FASEB J. 2017 Jul;31(7):2973-2980. doi: 10.1096/fj.201601183R. Epub 2017 Mar 24.
FASEB J. 2017.
PMID: 28341636
Free PMC article.
In conclusion, LPCAT2 is a novel therapeutic target for newly categorized analgesic drugs; in addition, our data call for the re-evaluation of the clinical utility of PAF receptor antagonists.-Shindou, H., Shiraishi, S., Tokuoka, S. M., Takahashi Y., Harayama, T., A …
In conclusion, LPCAT2 is a novel therapeutic target for newly categorized analgesic drugs; in addition, our data call for the re-evaluation …